Quercetin
Quercetin is a flavonol polyphenol found widely across the plant kingdom — onions, apples, broccoli, tomatoes, capers, and black tea are among the richest dietary sources. It is one of the most abundant flavonoids in the human diet and among the most extensively studied polyphenols in nutritional research. This research volume has generated considerable marketing activity, with quercetin promoted for cardiovascular health, immune function, anti-ageing effects, and senolytic activity. The clinical evidence base, however, is considerably less uniform than the marketing suggests, and the poor oral bioavailability of the standard aglycone form is a persistent limitation that affects the interpretation of much of the human trial data.
What it is
Quercetin belongs to the flavonol subclass of flavonoids and is characterised by three hydroxyl groups on its B-ring and C-ring structure that confer its antioxidant activity. It is found in plants both as the free aglycone and as various glycoside conjugates — quercetin-3-O-glucoside (isoquercetin), quercetin-3-O-rutinoside (rutin), and others. These forms have substantially different bioavailability: glycoside conjugates are in general better absorbed than the free aglycone, which is the form found in most commercial supplements. Bioavailability of the standard aglycone is estimated at approximately 20 percent or less from a typical supplement dose, and is highly variable between individuals, affected by gut microbiota composition, food matrix, and formulation. This variability is not merely a pharmacokinetic detail — it fundamentally limits the dose-response conclusions that can be drawn from trials using standard quercetin.
The proposed mechanisms of action are numerous and span multiple physiological systems. These include inhibition of pro-inflammatory transcription factors including NF-kB, inhibition of histamine release from mast cells relevant to allergic responses, inhibition of certain CYP450 enzymes, antioxidant free-radical scavenging, activation of SIRT1 pathways proposed to be relevant to longevity biology, and induction of apoptosis in senescent cells via Bcl-2 family protein inhibition. This last mechanism — the senolytic pathway — has attracted particular attention in the longevity space. Each proposed mechanism is plausible and has preclinical support, but their relative contribution to clinical outcomes at the concentrations achieved with oral supplementation of standard quercetin has not been established.
What the evidence shows
The most rigorous overview of quercetin's cardiometabolic effects is the umbrella review by Arabi et al. (2023, Phytotherapy Research), which synthesised five meta-analyses incorporating 18 eligible RCTs using GRADE methodology. The conclusion is direct: quercetin supplementation significantly reduces systolic blood pressure (SBP; WMD −1.9 mmHg, 95% CI −3.2 to −0.6) and insulin levels (WMD −1.07 μIU/mL, 95% CI −1.9 to −0.1), but does not significantly affect diastolic blood pressure, lipid profile, inflammatory markers, anthropometric indices, fasting glucose, or HOMA-IR. The certainty of evidence ranged from very low to moderate across outcomes. The SBP effect of approximately 2 mmHg is modest, falls within a range that is not clearly clinically meaningful at the individual level, and should be treated as a reproducible but fragile biomarker signal rather than a robust clinical effect. The insulin result is based on limited trials with high heterogeneity and its clinical significance is uncertain; it should not be read as evidence of metabolic benefit.
Earlier meta-analyses — including a 2016 Journal of the American Heart Association analysis of nine RCT arms and a 2022 meta-analysis of ten trials — reported more favourable results across both SBP and DBP. However, the 2016 analysis found that removing a single high-leverage trial by Zahedi et al. eliminated the significance of both blood pressure outcomes, indicating fragility of the pooled results. The 2022 analysis found significant DBP reduction only in the pre-hypertensive and hypertensive subgroup, not overall. These patterns are characteristic of a literature with high heterogeneity and limited robustness.
For inflammatory markers — one of the most widely promoted quercetin claims — the umbrella review found no significant effect on CRP or other inflammatory biomarkers when evidence is pooled and GRADE-rated. Individual trials have reported reductions in inflammatory markers, but these are not replicated consistently and likely reflect small-study heterogeneity rather than a reliable effect of standard quercetin.
The senolytic framing of quercetin deserves direct treatment. Quercetin inhibits anti-apoptotic Bcl-2 family proteins in preclinical models, promoting clearance of senescent cells. This mechanism has been demonstrated in vitro and in animal studies. In humans, the available clinical data on senolytic activity almost entirely comes from the dasatinib plus quercetin combination (D+Q), not quercetin alone. A first-in-human pilot trial in idiopathic pulmonary fibrosis used D+Q and found reductions in senescent cell markers. A 2025 single-arm pilot study in older adults with mild cognitive impairment and slow gait (STAMINA, eBioMedicine) used D+Q at intermittent dosing over 12 weeks and found the regimen safe and feasible, with some exploratory signals in functional and biomarker outcomes. These are combination therapy data: the specific contribution of quercetin to senescent cell clearance, independent of dasatinib, has not been established in human trials. Quercetin alone has not been tested as a senolytic in adequately powered clinical trials.
Five questions
Does low status cause harm? Quercetin is not an essential nutrient and there is no deficiency state. Dietary intake varies considerably depending on fruit and vegetable consumption, but low quercetin intake has not been associated with specific adverse health outcomes independent of overall dietary quality. There is no evidence that supplementing to raise quercetin intake corrects a functional insufficiency.
Does supplementation prevent disease? No human evidence supports disease prevention from quercetin supplementation. Observational studies associating higher dietary flavonoid intake with lower cardiovascular disease risk are confounded by overall dietary quality and cannot be attributed to quercetin specifically. No adequately powered prevention trial has been conducted with quercetin supplementation.
Does it affect biomarkers? Yes, selectively and modestly. Systolic blood pressure is the least inconsistent biomarker signal in the literature, though modest in magnitude and not clearly clinically meaningful at the individual level, and most apparent in hypertensive subgroups at doses above 500 mg/day. Insulin levels show a modest reduction in the umbrella review. Other cardiometabolic biomarkers including DBP, lipids, fasting glucose, and inflammatory markers are not significantly affected when evidence is pooled and quality-assessed. As surrogateOnly is set to true, these biomarker changes should not be presented as equivalent to clinical cardiovascular or metabolic benefit.
Does it help clinical populations? The most consistent signal is in hypertensive or pre-hypertensive populations, where blood pressure effects appear more reliable. Evidence in other clinical populations — people with established cardiovascular disease, metabolic syndrome, or cancer — is insufficient or based on trials too small and heterogeneous to support conclusions. The senolytic combination data in older adults with frailty and cognitive impairment represent an interesting research direction but cannot yet be interpreted as evidence of quercetin efficacy in those populations.
Does it benefit healthy individuals? Evidence of meaningful benefit in normotensive healthy individuals is weak. Blood pressure effects in normotensive subgroups are smaller and less consistent. The antioxidant and anti-inflammatory mechanisms are theoretically active in healthy people but have not translated into consistent measurable outcomes in controlled trials. Given the poor and variable bioavailability of standard quercetin, the concentration-response relationship in healthy adults is particularly uncertain.
Individual variation
Bioavailability is the dominant source of individual variation for standard quercetin. Gut microbiota composition substantially affects quercetin metabolism — the conversion of quercetin glycosides and the production of ring-fission metabolites that may contribute to biological activity. This means that plasma quercetin concentrations from a given supplement dose will differ considerably between individuals. Unlike urolithin A (where the microbiome determines whether the active compound is produced at all), quercetin absorption is more universally present but highly variable in magnitude.
Baseline cardiovascular risk status modifies the blood pressure response. Trials consistently show larger effects in hypertensive and pre-hypertensive populations than in normotensive individuals, which is the expected pattern for any antihypertensive intervention and should not be interpreted as quercetin being particularly effective but rather as blood pressure effects being more detectable against a background of elevated baseline values.
Food matrix and co-administration with fat significantly affect quercetin absorption. Quercetin taken with fatty foods is better absorbed than in a fasted state. Piperine (from black pepper) increases quercetin bioavailability through P-glycoprotein inhibition, though this effect is modest compared to purpose-designed enhanced forms.
Sex-specific data are limited. Most trials include mixed-sex populations without sex-stratified analyses. Hormonal influences on flavonoid metabolism are plausible but not well characterised for quercetin specifically.
Testing and status assessment
There are no clinically available tests for quercetin status. Plasma quercetin can be measured in research settings and reflects recent dietary intake, but has no established reference range for supplementation decision-making and is not available through routine clinical laboratories. Blood pressure monitoring is the most practically useful monitoring measure for anyone using quercetin for cardiovascular purposes, though the modest expected effects are near the threshold of meaningful detection in an individual.
Safety
Standard quercetin at doses of 500 to 1,000 mg per day is generally well tolerated in short-term clinical trials, with adverse events similar in frequency to placebo groups. Headache, tingling sensations, and mild gastrointestinal discomfort have been reported but are not consistently differentiated from placebo rates.
The drug interaction profile is the primary safety concern for supplemental doses. Quercetin inhibits CYP3A4, CYP2C9, and CYP2D6 enzymes in vitro, and at supplement doses these inhibitory effects create plausible and potentially clinically relevant risk of reduced clearance for drugs metabolised by these pathways — though the magnitude is best established for warfarin and immunosuppressants and less characterised for other drug classes. This includes warfarin (CYP2C9 substrate), cyclosporine and tacrolimus (CYP3A4 substrates), many statins, certain antidepressants, calcium channel blockers, and numerous other commonly prescribed medications. In vitro studies show quercetin displacement of warfarin from serum albumin binding sites and inhibition of CYP2C9-mediated warfarin metabolism; one clinical case report documents significant INR elevation in a patient combining quercetin and warfarin. Cyclosporine levels may be altered unpredictably, with both increases and decreases reported depending on dosing context, making this combination unreliable in transplant or autoimmune disease management. People on any drug with a narrow therapeutic index, particularly anticoagulants and immunosuppressants, should not use quercetin supplements without clinical oversight.
Quercetin's antiplatelet activity is documented in vitro and may add to the anticoagulant effect of warfarin, aspirin, or other antiplatelet agents through a second, pharmacodynamic mechanism. The combination of pharmacokinetic and pharmacodynamic anticoagulant interactions makes the warfarin-quercetin combination one of the more concrete supplement-drug interaction concerns across the supplement literature.
Pregnancy safety data are absent. Quercetin has demonstrated mutagenic effects in some in vitro and animal model contexts at high concentrations, though this has not been confirmed as clinically relevant at supplemental doses. Given the absence of safety data and the pharmacological activity of quercetin on multiple signalling pathways, avoidance in pregnancy is appropriate.
Long-term safety beyond 12 weeks has not been systematically studied in randomised controlled trials. Most published human data involve 8 to 12 week interventions. The safety profile for chronic use is not established.
What can reasonably be concluded
Quercetin is one of the most extensively studied dietary polyphenols in human trials, and the evidence base is more developed than for many supplements. The most defensible clinical claim — modest reduction in systolic blood pressure of approximately 2 mmHg — is consistent across multiple meta-analyses but falls within a range that is not clearly clinically meaningful at the individual level and is most apparent in hypertensive subgroups at doses above 500 mg/day.
The broader cardiometabolic claims that dominate quercetin marketing — anti-inflammatory effects, lipid-lowering, glucose control, and comprehensive cardiovascular protection — are not supported when the evidence is pooled and quality-assessed by an umbrella review. The senolytic claim is based entirely on the dasatinib plus quercetin combination and cannot be attributed to quercetin alone. The very poor and variable bioavailability of standard quercetin aglycone adds a fundamental limitation to interpreting dose-response relationships from the clinical literature.
An Emerging rating reflects a genuine but modest and bioavailability-limited signal in a narrow range of cardiometabolic biomarkers, against a background of inconsistent and generally low-quality evidence across the broader outcome domains that drive supplement marketing. The enhanced bioavailability forms covered in the companion entry have a more developed and specific clinical evidence base and should not be conflated with the standard aglycone.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.